Publications

Journal Article
Review
Ppublish 2 citations
Open access — free full text available
Open access
Electronic publication date
July 28, 2026

View on Pubmed.gov 42508841 | View on doi.org 10.1016/j.jcin.... (full text)

Retrograde CTO PCI via Epicardial Collaterals: Techniques, Tools, and Risk Mitigation.

Search for publications in this journal JACC Cardiovasc Interv - 19(14):1847-1863

Abstract

The retrograde approach to percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs) is a technically demanding strategy that requires specialized expertise and knowledge. Septal collaterals are generally considered the safest route given their intramuscular course, which can help contain blood extravasation in the event of perforation. However, when septal navigation is not feasible and no other options remain, epicardial collaterals provide a valuable alternative route to achieve successful revascularization. Although CTO PCI via epicardial collaterals is more complex and carries a higher risk of serious complications, innovations such as low-profile microcatheters and specialized low tip load guidewires have significantly enhanced both safety and technical feasibility. Consequently, retrograde CTO PCI via epicardial collaterals represents an important alternative when no other options are available and, when performed by experienced operators, allows complete revascularization even in the most challenging anatomies. Given this background, the present review provides practical guidance for interventionalists, outlining the current state of the art in terms of devices and techniques for CTO PCI via epicardial collaterals, including recommendations for complication prevention and management.

References

No references provided.

Conflict of interest statement

Funding Support and Author Disclosures Dr Agostoni has received consulting honoraria from Abbott, Boston Scientific, Cordis, iVascular, Medtronic, Neovasc, Seven Sons, Shockwave, Teleflex, and Terumo. Dr Goktekin has received consulting, speaker, and proctoring honoraria from Boston Scientific, Medtronic, MicroPort, and Asahi Intecc. Dr di Mario has received research or educational grants from Abbott Laboratories, Amgen, Asahi Intecc, AstraZeneca, Boston Scientific, Cardinal Health, Behring, Chiesi, Daiichi-Sankyo, Edwards Lifesciences, Medtronic, Menarini, Pfizer, Sanofi, Shockwave Medical, Teleflex, and Volcano-Philips. Dr Mashayekhi has received consulting, speaker, and proctoring honoraria from Abbott, Abiomed, Asahi Intecc, AstraZeneca, Biotronik, Boston Scientific, Cardinal Health, Daiichi-Sankyo, Medtronic, OrbusNeich, Shockwave Medical, Teleflex, and Terumo. Dr Diletti has received consulting and proctoring honoraria from Asahi Intecc, Terumo, IMDS, Teleflex, and Philips; speaker fees from Abbott, ACIST Medical Systems, Biotronik, Boston Scientific, and Medtronic; institutional research grants from ACIST Medical Systems, Biotronik, Boston Scientific, and Medtronic; and is a member of an advisory board at Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Copyright

Copyright © 2026 The Authors. Published by Elsevier Inc. All rights reserved.